Sector Focus


Caliber has successfully planned with both venture backed private development stage companies and publicly traded biopharmaceutical companies. We understand the unique challenges of emerging companies as well as global biotech organizations and we have developed a keen sense of what it takes to discover and develop biologically derived treatments to enhance the quality of care in markets with substantially under met medical needs.



Lysogene continues to make extraordinary progress and has nurtured meaningful relationships with key stakeholders worldwide. Its unparalleled expertise covers the cutting edge and relevant areas of gene therapy and orphan drug development: Basic research: We have a thorough understanding of viral gene transfer and the design of therapeutic vectors suitable for clinical development. Pre-clinical development: Lysogene has the specific know-how and expertise required for gene therapy, pre-clinical efficacy, toxicology and bio-distribution studies in small and large animal models. We collaborate with distinguished academic groups dedicated to this field of development.

Search Projects